{"id":"pf04965842","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PF04965842 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine. This leads to a decrease in blood glucose levels, making it a potential treatment for diabetes.","oneSentence":"PF04965842 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:25.614Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06807281","phase":"PHASE3","title":"A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-02","conditions":"Atopic Dermatitis","enrollment":500},{"nctId":"NCT06807268","phase":"PHASE3","title":"A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-07-24","conditions":"Eczema","enrollment":150},{"nctId":"NCT03422822","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-08","conditions":"Dermatitis, Atopic","enrollment":3166},{"nctId":"NCT05466578","phase":"","title":"Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)","status":"AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":"Severe Uncontrolled Atopic Dermatitis","enrollment":""},{"nctId":"NCT03915496","phase":"PHASE2","title":"Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-18","conditions":"Atopic Dermatitis","enrollment":46},{"nctId":"NCT03796676","phase":"PHASE3","title":"JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-02-18","conditions":"Atopic Dermatitis","enrollment":287},{"nctId":"NCT03660241","phase":"PHASE1","title":"A Renal Impairment Study for PF-04965842","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-10-05","conditions":"Renal Impairment","enrollment":23},{"nctId":"NCT03627767","phase":"PHASE3","title":"Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-06-11","conditions":"Dermatitis, Dermatitis, Atopic, Eczema","enrollment":1235},{"nctId":"NCT03720470","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-10-29","conditions":"Dermatitis, Dermatitis, Atopic, Eczema","enrollment":838},{"nctId":"NCT03626415","phase":"PHASE1","title":"A Hepatic Impairment Study for PF-04965842.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-10-01","conditions":"Hepatic Impairment","enrollment":24},{"nctId":"NCT03575871","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-06-29","conditions":"Dermatitis, Atopic","enrollment":391},{"nctId":"NCT03647670","phase":"PHASE1","title":"A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-03","conditions":"Phase 1","enrollment":25},{"nctId":"NCT03662516","phase":"PHASE1","title":"A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-26","conditions":"Healthy Females","enrollment":17},{"nctId":"NCT03637790","phase":"PHASE1","title":"Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-13","conditions":"Healthy","enrollment":12},{"nctId":"NCT03742336","phase":"PHASE1","title":"Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-21","conditions":"Healthy","enrollment":20},{"nctId":"NCT03796182","phase":"PHASE1","title":"Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT04065633","phase":"PHASE1","title":"Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Dermatitis, Atopic","enrollment":46},{"nctId":"NCT04099563","phase":"PHASE1","title":"Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-10-14","conditions":"HEALTHY","enrollment":13},{"nctId":"NCT03349060","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-12-07","conditions":"Dermatitis, Atopic","enrollment":387},{"nctId":"NCT03937258","phase":"PHASE1","title":"A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-05-21","conditions":"Healthy","enrollment":12},{"nctId":"NCT03386279","phase":"PHASE1","title":"A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-02","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT03806101","phase":"PHASE1","title":"Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-23","conditions":"Healthy","enrollment":12},{"nctId":"NCT02780167","phase":"PHASE2","title":"Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-04","conditions":"Atopic Dermatitis","enrollment":269},{"nctId":"NCT03634345","phase":"PHASE1","title":"Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-12","conditions":"Dermatitis, Atopic","enrollment":24},{"nctId":"NCT03250039","phase":"PHASE1","title":"Absorption, Metabolism, Excretion and Absolute Bioavailability","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-10","conditions":"Healthy","enrollment":6},{"nctId":"NCT02201524","phase":"PHASE2","title":"Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2014-11","conditions":"Plaque Psoriasis","enrollment":59},{"nctId":"NCT02163161","phase":"PHASE1","title":"AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-06","conditions":"Healthy","enrollment":12},{"nctId":"NCT01835197","phase":"PHASE1","title":"First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05","conditions":"Healthy","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PF04965842","genericName":"PF04965842","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PF-04965842 is a small molecule inhibitor of the tyrosine-protein kinase JAK1. It is being studied in clinical trials for various conditions, including severe uncontrolled atopic dermatitis and hepatic impairment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}